文献速递妇科

低级别浆液性卵巢癌的基因组图谱分析:识别用于疾病诊断和治疗的新标志物

Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy.
PubMed 文献 · Gynecol Oncol · 2022-10-11

研究对组织学确认的低级别浆液性卵巢癌(LGSOC)标本进行统一分子检测,179份标本经Caris Life Sciences评估,153份经二次独立组织学复核确认。最常见突变为MAPK通路基因KRAS(23.7%,n=36)、NRAS(11.2%,n=19)、NF1(7.9%,n=5)和BRAF(6.6%,n=10)。雌激素受体表达80.2%(n=130),孕激素受体表达27.8%(n=45);激素阴性标本中近50%携带KRAS或NF1突变,无NRAS突变。免疫治疗应答标志物低至缺失。

要点

  • LGSOC中最常见突变为MAPK通路成员:KRAS 23.7%、NRAS 11.2%、NF1 7.9%、BRAF 6.6%。
  • BRAF突变中Class III突变3例,Class I V600E突变7例(共10例BRAF突变)。
  • 激素阴性标本中近50%为KRAS或NF1突变,无NRAS突变;免疫治疗标志物低至缺失。

核心结论

  • BRAF突变率低于传统报告水平。
  • MAPK激活增加导致ERα配体非依赖性激活,激素阴性标本中49.2%为KRAS或NF1突变,作者认为应考虑激素治疗与靶向治疗联合。
  • 免疫治疗生物标志物缺失,提示免疫治疗药物获益有限。

研究设计与样本

  • 对组织学确认的LGSOC队列进行统一分子检测,采用热点突变和全外显子组下一代测序(NGS)、RNA融合基因分析、片段分析、原位杂交和/或免疫组化,由Caris Life Sciences(Phoenix, AZ)评估179份标本。
  • 第二项独立组织学复核确认153份标本的组织学。

主要发现

  • 突变频率≥5%的基因均为丝裂原活化蛋白激酶(MAPK)通路成员:KRAS 23.7%(n=36)、NRAS 11.2%(n=19)、NF1 7.9%(n=5)、BRAF 6.6%(n=10)。
  • 10例BRAF突变中,Class III突变3例,Class I V600E突变7例。
  • 雌激素受体表达80.2%(n=130),孕激素受体表达27.8%(n=45)。
  • 激素阴性标本中近50%携带KRAS或NF1突变,无NRAS突变。
  • 免疫治疗应答标志物低至缺失。

临床怎么用

  • 作者认为,鉴于MAPK激活增加导致ERα配体非依赖性激活,且49.2%的激素阴性标本为KRAS或NF1突变,应考虑激素治疗与靶向治疗联合。
  • 作者认为免疫治疗生物标志物缺失提示免疫治疗药物获益有限。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Low grade serous ovarian cancer (LGSOC) differs from high grade serous in terms of pathogenesis, molecular, genetic, and clinical features. Molecular studies have been hampered by small sample sizes, heterogenous histology, and lack of comprehensive testing. We sought to molecularly profile LGSOC in a homogenously tested, histologically confirmed cohort. METHODS: Using hot-spot and whole exome next generation sequencing (NGS), fusion gene analysis interrogating RNA, fragment analysis, in situ hybridization and/or immunohistochemistry, 179 specimens were evaluated by Caris Life Sciences (Phoenix, AZ). A second independent histologic review confirmed histology in 153 specimens. RESULTS: Most frequently mutated genes (5% or greater) were members of the mitogen-activated protein kinase (MAPK) pathway: KRAS (23.7%, n = 36), NRAS (11.2%, n = 19), NF1 (7.9%, n = 5), and BRAF (6.6%, n = 10). Class III mutations were seen in 3 of 10 BRAF mutations while 7 were Class I V600E. Overall, estrogen and progesterone receptor expression was 80.2% (n = 130) and 27.8% (n = 45), respectively. Of those that were hormone negative, nearly 50% contained KRAS or NF1 mutations. None were NRAS mutated. Markers of response to immunotherapy were low to absent. CONCLUSION: BRAF mutations were seen to be lower than those traditionally reported. With increased MAPK activation resulting in ligand independent activation of ERα, a role of combination therapy with hormonal and targeted therapy should be considered as 49.2% of hormone negative specimens were KRAS or NF1 mutated. Absence of immunotherapy biomarkers suggest limited benefit to immunotherapeutic agents.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. ElNaggar A, Robins D, Baca Y, et al. Genomic profiling in low grade serous ovarian cancer: Identification of novel markers for disease diagnosis and therapy. Gynecol Oncol. 2022. PMID: 36229265. doi:10.1016/j.ygyno.2022.09.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。